Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 284

1.

Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis.

Celum C, Baeten JM.

Antivir Ther. 2012;17(8):1483-93. doi: 10.3851/IMP2492. Epub 2012 Dec 7. Review.

2.

Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.

Okwundu CI, Uthman OA, Okoromah CA.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD007189. doi: 10.1002/14651858.CD007189.pub3. Review.

PMID:
22786505
3.

Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.

Celum C, Baeten JM.

Curr Opin Infect Dis. 2012 Feb;25(1):51-7. doi: 10.1097/QCO.0b013e32834ef5ef. Review.

4.

Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.

Plosker GL.

Drugs. 2013 Mar;73(3):279-91. doi: 10.1007/s40265-013-0024-4. Review.

PMID:
23444256
5.

Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention.

van der Straten A, Van Damme L, Haberer JE, Bangsberg DR.

AIDS. 2012 Apr 24;26(7):F13-9. doi: 10.1097/QAD.0b013e3283522272.

PMID:
22333749
6.

Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis.

Baeten J, Celum C.

Annu Rev Med. 2013;64:219-32. doi: 10.1146/annurev-med-050911-163701. Epub 2012 Sep 27. Review.

7.

Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study.

Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin Í, Delany S, Garnett GP, Gray G, Johnson L, McIntyre J, Rees H, Celum C.

PLoS Med. 2011 Nov;8(11):e1001123. doi: 10.1371/journal.pmed.1001123. Epub 2011 Nov 15.

8.

Pre-exposure prophylaxis (PrEP) in HIV-uninfected individuals with high-risk behaviour.

Nadery S, Geerlings SE.

Neth J Med. 2013 Jul-Aug;71(6):295-9. Review.

9.

Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.

Murnane PM, Brown ER, Donnell D, Coley RY, Mugo N, Mujugira A, Celum C, Baeten JM; Partners PrEP Study Team.

Am J Epidemiol. 2015 Nov 15;182(10):848-56. doi: 10.1093/aje/kwv202. Epub 2015 Oct 19.

PMID:
26487343
10.

Preexposure prophylaxis for HIV prevention: where have we been and where are we going?

Baeten JM, Haberer JE, Liu AY, Sista N.

J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S122-9. doi: 10.1097/QAI.0b013e3182986f69. Review.

11.

Pre-exposure chemoprophylaxis of HIV infection: quo vadis?

Clercq ED.

Biochem Pharmacol. 2012 Mar 1;83(5):567-73. doi: 10.1016/j.bcp.2011.10.016. Epub 2011 Oct 29.

PMID:
22067069
12.

Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.

Kibengo FM, Ruzagira E, Katende D, Bwanika AN, Bahemuka U, Haberer JE, Bangsberg DR, Barin B, Rooney JF, Mark D, Chetty P, Fast P, Kamali A, Priddy FH.

PLoS One. 2013 Sep 26;8(9):e74314. doi: 10.1371/journal.pone.0074314. eCollection 2013.

13.

HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.

Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, Mujugira A, Mugo N, Ndase P, Hendrix C, Celum C.

J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):340-8. doi: 10.1097/QAI.0000000000000172.

14.

Willingness of Kenyan HIV-1 serodiscordant couples to use antiretroviral-based HIV-1 prevention strategies.

Heffron R, Ngure K, Mugo N, Celum C, Kurth A, Curran K, Baeten JM.

J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):116-9. doi: 10.1097/QAI.0b013e31825da73f.

15.

Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.

Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, Mujugira A, Tappero J, Kahle EM, Thomas KK, Baeten JM; Partners PrEP Study Team.

AIDS. 2013 Aug 24;27(13):2155-60. doi: 10.1097/QAD.0b013e3283629037.

16.

Oral antiretroviral chemoprophylaxis: current status.

Baeten J, Celum C.

Curr Opin HIV AIDS. 2012 Nov;7(6):514-9. doi: 10.1097/COH.0b013e3283582d30. Review.

17.

Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.

Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, Tumwesigye E, Psaros C, Safren SA, Ware NC, Thomas KK, Donnell D, Krows M, Kidoguchi L, Celum C, Bangsberg DR.

PLoS Med. 2013;10(9):e1001511. doi: 10.1371/journal.pmed.1001511. Epub 2013 Sep 10.

18.

What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples.

Ware NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, Psaros C, Safren S, Tumwesigye E, Celum CL, Bangsberg DR.

J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):463-8. doi: 10.1097/QAI.0b013e31824a060b.

19.

The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis.

Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett TB.

AIDS. 2013 Jan 28;27(3):447-58. doi: 10.1097/QAD.0b013e32835ca2dd.

PMID:
23296196
20.

Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.

Donnell D, Hughes JP, Wang L, Chen YQ, Fleming TR.

J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S130-4. doi: 10.1097/QAI.0b013e3182986fac.

Items per page

Supplemental Content

Write to the Help Desk